Suramin hexasodium salt (Germanin, NSC 34936, SK 24728)

Size

50mg

References

Product Reference: \n?Suramin: a potent ATPase inhibitor which acts on the inside surface of the sodium pump: P.A. Fortes, et al.; Biochim. Biophys. Acta 318, 262 (1973)\n?Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses: E. De Clerq; Cancer Lett. 8, 9 (1979)\n?Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III: H. Mitsuya, et al.; Science 226, 172 (1984)\n?Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A: C.E. Hensey, et al.; FEBS Lett. 258, 156 (1989)\n?Suramin: prototype of a new generation of antitumor compounds: R.V. La Rocca, et al.; Cancer Cells 2, 106 (1990) (Review)\n?Suramin. A potent inhibitor of melanoma heparanase and invasion: M. Nakajima, et al.; J. Biol. Chem. 266, 9661 (1991)\n?Nature of the interaction of growth factors with suramin: C.R. Middaugh, et al.; Biochemistry 31, 9016 (1992)\n?The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1): R. Danesi, et al.; Pharmacol. Res. 25, 17 (1992)\n?Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro: H. Yamazaki, et al.; Prostate 23, 25 (1993)\n?Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities: G. Strassmann, et al.; Int. J. Immunopharmacol. 16, 931 (1994)\n?Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response: P. Leland, et al.; Oncol. Res. 7, 227 (1995)\n?Suramin analogues as subtype-selective G protein inhibitors: M. Freissmuth, et al.; Mol. Pharmacol. 49, 602 (1996)\n?PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors: S.J. Charlton, et al.; Br. J. Pharmacol. 118, 704 (1996)\n?Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action: J. Waltenberger, et al.; J. Mol. Cell Cardiol. 28, 1523 (1996)\n?Antiangiogenic and antiproliferative activity of suramin analogues: A.R. Gagliardi, et al.; Cancer Chemother. Pharmacol. 41, 117 (1998)\n?Suppression of myocardial inflammation using suramin, a growth factor blocker: T. Shiono, et al.; Circ. J. 66, 385 (2002)\n?Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro: K. Trieb & H. Blahovec; Int. J. Biochem. Cell Biol. 35, 1066 (2003)\n?Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo: M. Denkinger, et al.; Int. Immunopharmacol. 4, 15 (2004)\n?Functional regulation of the cardiac ryanodine receptor by suramin and calmodulin involves multiple binding sites: A.P. Hill, et al; Mol. Pharmacol. 65, 1258 (2004)\n?Modulation of adenylyl cyclase activity in young and adult rat brain cortex. Identification of suramin as a direct inhibitor of adenylyl cyclase: J. St